Immuno-epidemiological and Socio-behavioral Evaluation of Release of Sterile Male Aedes Albopictus Mosquitoes on Human-vector Contacts

Not Applicable

• Conditions: Mosquito Bite
• Interventions: Other: sterile insect technique (TIS)

• Registration Number: NCT05313126
• Lead Sponsor: Institut de Recherche pour le Developpement

Brief Summary

This trial is based on 2 complementary components, named ExpAlbo Biomarker and CAPAlbo Questionnaire

1. ExpAlbo Biomarker (Exposure to the Aedes albopictus mosquito): This component concerns the epidemiological evaluation of the effectiveness of the release of sterile male mosquitoes on the level of exposure of individuals to the bites of the tiger mosquito through the use of a new immunological biomarker of the human-vector contact, developed over the past 20 years by the IRD-MIVEGEC team. Indeed, when a person is bitten by a mosquito, he or she develops a defence reaction, called an immune reaction, against the mosquito's saliva. The main objective of this study is to measure this immune response, and more specifically the antibody response specifically directed against compounds (peptide = small fragment of a protein) in mosquito saliva, and to determine whether this anti-saliva antibody response, and therefore exposure to mosquito bites, decreases when the mosquito control strategy is applied.

2. CAPAlbo Questionnaire: This component is concerned with assessing the impact of sterile male mosquito releases on perceptions and practices related to exposure to Aedes albopictus based on population-based questionnaire surveys. The main objective of these surveys is to determine whether changes in objective exposure to Aedes albopictus mosquitoes are associated with changes in the perception of the nuisance and in the lifestyle habits of respondents, particularly those related to the prevention of mosquito bites (such as the use of repellents or mosquito nets).

Detailed Description

Not available

Study Timeline

• Study Start: 2021-11-09
• Study First Submitted: 2022-01-05
• Status Verified: 2022-03
• Study First Submitted QC: 2022-03-28
• Last Update Submitted: 2022-03-28
• Study First Posted: 2022-04-06
• Last Update Posted: 2022-04-06
• Primary Completion: 2023-06
• Study Completion: 2023-06

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

• To inhabit on a regular basis in the intervention/control area
• To speak French

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
sterile male Aedes albopictus-exposed	sterile insect technique (TIS)	Sterile male Aedes albopictus are released in the area.

Primary Outcome Measures

Name	Time	Method
Immunological indicators	12 months	Biomarker based on the measurement of human IgG antibody levels specific to one peptide of Aedes saliva (i.e. Nterm-24kDa salivary peptide)
Exposure to Aedes mosquito	12 months	self-perceived exposure to mosquito will be assessed by questionnaire

Secondary Outcome Measures

Name	Time	Method
Protective behavior	12 months	a composite indicator derived from a questionnaire will rate the protective behavior of the participants to avoid mosquito bites

Trial Locations

Locations (1)

population générale (quartier Duparc (Sainte Marie) et Quartier Bois rouge); 🇫🇷 La Réunion, France